Abstract
In the past seven years, a number of potentially useful approaches for the therapy of human immunodeficiency virus (HIV) infection have emerged.1–3 One such approach is the use of the broad family of 2′,3′-dideoxynucleosides (ddN) as therapeutic agents.4,5 3′-Azido-2′,3′dideoxythymidine (AZT or zidovudine), the first member of the dideoxynucleoside family administered to humans, has now been formally proven to reduce the morbidity and mortality of patients with acquired immunodeficiency syndrome (AIDS) and its related disorders.6–8 AZT has also been proven to benefit certain asymptomatic individuals infected with HIV-1 when administered in the early stages of HIV infection.9 It is worth noting that AZT has most recently been hown to be active at lower doses than that initially ministered.10,11 Two other analogs of the dideoxynucleoside family, 2′,3′-dideoxycytidine (ddC)12,13 and 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T),14 have also demonstrated activity against HIV-1 in some patients in Phase I clinical trials. A purine member, 2′,3′-dideoxyinosine (ddI or didanosine), has also recently been shown to be active against HIV-1 in patients with AIDS and advanced AIDS related complex (ARC) in short-term Phase I clinical trials, although notable adverse effects including painful peripheral neuropathy and acute pancreatitis have been observed.15–17 In this regard, certain doses of ddl which can confer antiviral effects on patients have been tolerated for more than 2 years without toxicity.18 ddI is now under phase II clinical trials in several countries.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
H. Mitsuya, R. Yarchoan, and S. Broder, Molecular targets for AIDS therapy. Science. 249: 1533 (1990).
H. Mitsuya and S. Broder, Strategies of antiviral therapy in AIDS. Nature. 325: 773 (1987).
R. Yarchoan, H. Mitsuya, C.E. Meyer, and S. Broder, Clinical pharmacology of 3’-azido-2’,3’dideoxythymidine (zidovudine) and related didexoynucleosides. N. Engl. J. Med. 321: 726 (1989).
H. Mitsuya, K.J. Weinhold, F.A. Furman, M.H. St. Clair, S.N. Lehrman, R.C. Gallo, D. Bolognesi, D.W. Barry, and S. Broder. 3’-Azido-3’-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA. 82: 7096 (1985).
H. Mitsuya and S. Broder, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus (HTLV-III/LAV) by 2’,3’dideoxynucleosides, Proc. Natl. Acad. Sci. USA. 83: 1911 (1986).
R. Yarchoan, R. Klecker, K.J. Weinhold, P.D. Markham, H.K. Lyerly, D.T. Durack, E. Gelmann, S.N. Lehrman, R.M. Blum, D.W. Barry, G.M. Shearer, M.A. Fischi, H. Mitsuya, R.C. Gallo, J.M. Collins, D.P. Bolognesi, C.E. Myers, and S. Broder, Administration of 3’-azido-3’deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex, Lancet, i, 575 (1986).
M.A. Fischi, D.D. Richman, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M.Leedom, J.E. Groopman, D. Mildvan, R.T. Schooley, G.G. Jackson, D.T. Durack, D. King, and the AZT Collaborative Group, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial, N. Engl. J. Med. 317: 185 (1987).
D.D. Richman, M.A. Fischi, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M.Leedom, J.E. Groopman, D. Mildvan, M.S. Hirsch, G.G. Jackson, D.T. Durack, S. NusinoffLehrman, and the AZT Collaborative Working Group. The toxicity of azidotymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A Double-blind, placebo-controlled trial. N. Engl. J. Med., 317: 192 (1987).
P.A. Volberding, S.W. Lagakos, M.A. Koch, C. Pettinelli, M.W. Myers, D.K. Booth, H.H. Balfour, Jr., R.C. Reichman, J.A. Bartlett, M.S. Hirsch, R.L. Murphy, W.D. Hardy, R. Soeiro, M.A. Fischi, J.G. Bartlett, T.C. Merigan, N.E. Hyslop, D.D. Richman, F.T. Valentine, L. Corey, and the AIDS Clinical Tirais Group of the National Institute of Allergy and Infectius Diseases. Zidovudin in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimete. N. Engl. J. Med. 322: 941 (1990).
M.A. Fischl, C.B. Parker, C. Pettinelli, M. Wulfsohn, M.S. Hirsch, A.C. Collier, D. Antoniskis, M. Ho, D.D. Richman, E. Fuchs, T.C. Merigan, R.C. Reichman, J. Gold, N. Steigbigel, G.S. Leoung, S. Rasheed, A. Tsiatis, and the AIDS clinical trials group, A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med. 323: 1009 (1990).
A.C. Collier, S. Bozzette, R.W. Coombs, D.M. Causey, D.A. Schoenfeld, S.A. Spector, C.B. Pettinelli, G. Davies, D.D. Richman, J.M. Leedom, P. Kidd, and L. Corey, A pilot study of low-dose zidovudine in human immunodeficiency virus infection, N. Engl. J. Med. 323: 1015 (1990).
R. Yarchoan, C.-F. Perno, R.V. Thomas, R.W. Klecker, J.P. Allain, J. Wills, N. McAtee, M.A. Fisch], R. Dubinski, M.C. McNeely, H. Mitsuya, J.M. Pluda, T.J. Lawley, M. Leuther, B. Safai, J.M. Collins, C.E. Myers, and S. Broder, Phase I studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT), Lancet i: 76 (1988).
T.C. Merigan, G. Skowron, S.A. Bozzette, D.D. Richman, R. Uttamchandani, M. Fischl, R. Schooley, M. Hirsch, W. Soo, C. Pettinelli, H. Schaumburg, and the ddC Study Group of the AIDS Clinical Trials Group, Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study, Ann. Int. Med. 110:189 (1989).
M. Browne, G. Curt, and Brown University Phase I working group; unpublished data.
R. Yarchoan, H. Mitsuya, R.V. Thomasm J.M. Pluda, N.R. Hartman, C.-F. Perno, K.S. Marczyk, J.- P. Allin, D.G. Johns, and S. Broder. In vivo activity against HIV and favorable toxicity profile of 2’,3’-dideoxyinosine, Science 245:412 (1989).
J.S. Lambert, M. Seidlin, R.C. Reichman, C.S. Plank, M. Laverty, G.D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F.T. Valentine, R. Dolin, 2’,3’-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex, N. Engl. J. Med. 322: 1333 (1989).
T.P. Cooley, L.M. Kunches, C.A. Saunders, J.K. Ritter, C.J. Perkins, C. McLaren, R.P. McCaffrey, H.A. Liebman, Once-daily administration of 2’,3’-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex, N. Engl. J. Med. 322: 1340 (1990).
R. Yarchoan, J.M. Pluda, R.V. Thomas, H. Mitsuya, P. Browers, K.M. Wyvill, N. Hartman, D.G.Johns, and S. Broder. Long-term toxicity/activity profile of 2’,3’-dideoxyinosine in AIDS or AIDS-related complex. Lancet, ii, 526 (1990).
W.D. Snider, D.M. Simpson, S. Nielsen, J.W.M. Gold, C.E. Metroka, J.B. Posner. Neurological complications of Acquired Immune Deficiency Syndrome: Analysis of 50 patients. Ann. Neurol. 14: 403 (1983).
I.J. Koralnik, A. Beaumanoir, R. Häusler, A. Kohler, A.B. Safran, R. Delacoux, D. Vibert, E. Mayer, P. Burkhard, A. Nahory, M. Magistris, J. Sanches, P. Myers, F. Paccolat, F. Quoex, V. Gabriel, L. Perrin, B. Mermillod, G. Gauthier, F. A. Waldvogel, B. Hirshel. A controlled study of early neurologic abnormalities in men with asymptomatic human immunodeficiency virus infection. N. Engl. J. Med., 323: 864 (1990).
S. Gartner, P. Markovits, D.M. Markovits, M. H. Kaplan, R.C. Gallo, and M. Popovic, The role of mononuclear phagocytes in HTLV-III/LAV infection, Science, 233: 215 (1986).
S. Koenig, H.E. Gendelman, J.M. Orenstein, M.C. Dal Canto, G.H. Pezeshpour, M. Yungbluth, F. Janotta, A. Aksamit, M.A. Martin, and A.S. Fauti, Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy, Science, 233: 1089 (1986).
B.A. Watkins, H.H. Dorn, W.B. Kelly, R.C. Armstrong, B.J. Potts, F. Michaels, C V. Kuft, M. Dubois-dalcq, Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science, 249: 549 (1990).
T. Shirasaka, K. Murakami, H. Ford, Jr., J.A. Kelly, H. Yoshioka, E. Kojima, S. Aoki, S. Broder, and H. Mitsuya, Halogenated congeners of 2’,3’-dideoypurine nucleosides active against HIV in vitro: A new class of lipophilic prodrugs. Proc. Natl. Acad. Sci. USA. (in press).
K. Murakami, T. Shirasaka, H. Yoshioka, E. Kojima, H. Ford, J.S. Driscoll, J.A. Kelly, and H. Mitsuya. Escherichia coli-mediated biosynthesis and in vitro antiviral activity of lipophilic 6-halo-2’,3’-dideoxypurine nucleosides: A new class of prodrugs against HIV. (submitted).
H. M. Kalckar, The enzymatic synthesis of purine ribosides. J. Biol. Chem. 67: 477 (1947).
J.L. Ott, C.H. Werkman, Formation of adenosine by cell-free extracts of Escherichia coli, Arch. Biochem. Biophys. 48:483 (1954).
J.L. Ott, C.H. Werkman, Coupled nucleoside phosphorylase reactions in Escherichia coli, Arch. Biochem. Biophys. 69:264 (1957).
A. Imada and S. Igarashi, Ribosyl and deoxyribosyl transfer by bacterial enzyme systemsJ. Bacteriol. 94:1551 (1967).
K. Yokozeki, S. Yamanaka, T. Utagawa, K. Takinami, Y. Hirose, A Tanaka, K. Sonomoto, and S. Fukui, Production of adenine arabinoside by gel-entrapped cells of enterobacter aerogenes in water-organic cosolvent system, European J. Appl. Microbiol. Biotechnol. 14: 225, (1982).
T. Utagawa, H. Morisawa, F. Yoshinaga, A. Yamazaki, K. Mitsugi, and Y. Hirose, Microbial synthesis of purine arabinosides and their biological activity, Agric. Biol. Chem. 49: 2167 (1985).
H. Shirae, K. Kobayashi, H. Shiragami, Y. hie, N. Yasuda, and K. Yokozeki, Production of 2’,3’dideoxyadenosine and 2’,3’-dideoxyinosine from 2’,3’-dideoxyuridine and the corresponding purine bases by resting cells of Escherichia coli AJ 2595, Appl. Enviromental Micrbiol. 55: 419 (1989).
C.K. Chu, G.V. Ullas, L.S. Jeong, S.K. Ahn, B. Doboszewski, Z.K. Lin, J.W. Beach, R.F. Schinazi, Synthesis and structure-activity relationships of 6-substituted 2’,3’-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents, J. Med. Chem. 33: 1553 (1990).
R. Yarchoan, G. Berg, P. Brouwers, M.A. Fischi, A.R. Spitzer, A. Wichman, J. Grafman, R.V. Thomas, B. Safai, A. Brunetti, C.-F. Perno, P.J. Schmidt, S.M. Larson, C.E. Myers, and S. Broder, Response of human immunodeficiency virus-associated neurological disease to 3’-azido-3’deoxythymidine, Lancet. i: 132 (1987).
P.A. Pizzo, J. Eddy, J. Faloon, F. Balis, R.F. Murphy, H. Moss, P. Wolters, P. Browers, P. Jarosinski, M. Rubin, S. Broder, R. Yarchoan, A. Brunetti, M. Maha, S. Nusinoff-Lehrman, and D.G. Poplack, Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection, N. Engl. J. Med. 319: 889 (1988).
P.N. Craig, Interdependence between physical parameters and selection of substituent groups for correlations studies, J. Med. Chem, 14: 8 (1971).
B.M. Chassy and R.J. Suhadolnick. Adenosine aminohydrolase. J. Biol. Chem. 242:3655, (1967).
J.P. Horwitz, J. Chua, and M. Noel. Nucleosides, V. The monomesylates of 1-(2’-deoxy-b-Dlyxofuranosyl) thymine. J. Org. Chem. 29: 2076 (1964).
M.J. Robins and R.K. Robins. The synthesis of 2’,3’-dideoxyadenosine from 2’-deoxyadenosine. J. Am. Chem. Soc. 86:3585 (1964).
J.P. Horwitz, J. Chua, M. Noel, and J.T. Donatti, Nucleosides. XI. 2’,3’-DideoxycytidineJ. Org. Chem.32:817 (1966).
T.S. Lin and W.H. Prusoff, Synthesis and biological activity of several amino analogues of thymidine, J. Med. Chem. 21: 109 (1978).
K. Murakami, H. Yoshioka, E. Kojima, et al.Unpublished data.
H. Ford, Jr., C.L. Merski, and J.A. Kelley. Abstracts of papers, 41st Pittsburgh Conference, New York, NY; The Pittsburgh Conference: Pittsburgh, PA, Abstract, 1174 (1990).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Shirasaka, T. et al. (1991). Lipophilic 6-Halo-2′,3′-Dideoxypurine Nucleosides: Potential Antiretroviral Agents Targeting HIV-Associated Neurologic Disorders. In: Kumar, A. (eds) Advances in Molecular Biology and Targeted Treatment for AIDS. GWUMC Department of Biochemistry Annual Spring Symposia. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5928-9_30
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5928-9_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5930-2
Online ISBN: 978-1-4684-5928-9
eBook Packages: Springer Book Archive